Melanotan II Research Hub · Evidence Overview
Melanotan II research evidence: melanocortin-receptor signaling and study limitations
A source-based review of receptor pharmacology, early human studies, animal models, and the limits of what those studies establish.
Evidence at a glance
What is Melanotan II?
Melanotan II, commonly abbreviated MT-II, is a lactam-bridged cyclic peptide derived from the central sequence of alpha-melanocyte-stimulating hormone. Early chemistry and pharmacology work described it as a potent melanotropic analogue with activity at several melanocortin receptor subtypes.
That lack of receptor selectivity is central to interpreting the literature. Results involving pigmentation, neural signaling, appetite-related behavior, or other physiological responses may arise through different receptor populations and experimental contexts. A finding in one model cannot be treated as a general claim about the compound.
Evidence map
| Research area | What was studied | Key limitation |
|---|---|---|
| Early human research | A three-volunteer phase I pilot examined pigmentation and short-term tolerability under a controlled protocol. | The sample was extremely small and was not designed to establish broad safety or clinical use. |
| Controlled crossover research | A study in ten men compared Melanotan II with placebo and recorded physiological responses and adverse effects. | The narrow population and short observation period limit generalization. |
| Cell signaling | MC4R experiments compared the duration of cAMP signaling after exposure to natural and synthetic agonists. | Cell-line signaling does not establish whole-organism effects. |
| Animal neuroscience | Rodent studies examined hindbrain and nucleus-accumbens melanocortin pathways involved in feeding behavior. | Species, brain region, route, and behavioral paradigm constrain interpretation. |
| Medicinal chemistry | Researchers modified the cyclic scaffold to study binding and functional selectivity at human melanocortin receptors. | Analogue design results do not establish outcomes for the parent compound. |
Melanocortin-receptor signaling
Melanocortin receptors are G protein-coupled receptors with distinct tissue distributions and physiological roles. Melanotan II is generally described as a potent, nonselective agonist rather than a receptor-specific probe. That makes it useful for studying the melanocortin system, but it also complicates attribution of an observed effect to a single receptor subtype.
A 2015 cell study compared the timing of MC4R signaling after exposure to natural and synthetic agonists. In that model, Melanotan II produced persistent cAMP signaling after the compound was removed, unlike the shorter response observed with alpha-MSH. The result is evidence about signaling kinetics in particular cell systems, not proof of a clinical effect.
Medicinal-chemistry research published in 2022 used the Melanotan II scaffold to explore how alternative cyclization strategies changed receptor affinity and functional selectivity. This work reinforces that small structural changes can materially alter receptor behavior, so identity and purity are necessary but separate analytical questions.
What the small clinical studies reported
A 1996 pilot phase I study enrolled three male volunteers under a single-blind, placebo-controlled protocol. It reported pigmentation changes and several short-term effects. The study provides historical evidence that the peptide was investigated in humans, but its size and design are far too limited to establish general safety or effectiveness.
A 2000 double-blind crossover study enrolled ten men with erectile dysfunction and organic risk factors. Investigators recorded physiological responses, self-reported desire, and adverse effects during a six-hour monitoring period. Nausea and stretching or yawning occurred more often with Melanotan II, and severe nausea occurred in some administrations. This is a narrow, early clinical experiment, not a basis for use outside research oversight.
What neural-circuit studies add
A 2014 rat study examined whether central vagal afferent endings participate in the reduction of food intake after activation of melanocortin-3/4 receptors in the nucleus of the solitary tract. The researchers used localized administration, signaling measurements, and surgical manipulation to test a specific pathway.
A 2022 mouse study microinjected Melanotan II into the nucleus accumbens and evaluated consumption and motivation to obtain food. The reported behavioral changes help map melanocortin signaling in a defined neural circuit. They do not predict an outcome from a different preparation, route, species, or research setting.
Analytical and documentation considerations
A literature summary cannot verify the identity of a physical sample. Laboratory procurement should connect the vial label and lot number to a lot-specific Certificate of Analysis and evaluate the methods used for identity, purity, and measured content.
- Match the compound name, labeled quantity, lot number, and report identifier.
- Review purity and identity as separate analytical questions.
- Compare the labeled quantity with measured net peptide content.
- Retain the original laboratory report and verification information with the research record.
For JD BioWorks lot 2026-003, the ILS Laboratories report identifies Melanotan II, a labeled quantity of 10 mg, 99.94% peptide purity, 10.35 mg net peptide content, identity confirmed by HPLC retention-time matching, and fentanyl not detected. Those results describe the submitted sample only.
Major limitations in the evidence base
- The available human studies are small, early, and narrow in scope.
- Cell and animal results do not establish human outcomes.
- Nonselective receptor activity complicates claims about mechanism.
- Clinical research materials and protocols are not interchangeable with commercial research samples.
- Published research does not provide a basis for human or veterinary use of JD BioWorks materials.
Verified sources
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. PubMed PMID 8637402.
- Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000. PubMed PMID 11018622.
- Molden BM, et al. Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists. Mol Endocrinol. 2015. PubMed PMID 26418335.
- Campos CA, et al. Central vagal afferent endings mediate reduction of food intake by melanocortin-3/4 receptor agonist. J Neurosci. 2014. PubMed PMID 25232103.
- Tomassi S, et al. CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. J Med Chem. 2022. PubMed PMID 35188390.
- Eliason NL, et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022. PubMed PMID 36155088.
Research record
- Compound
- Melanotan II (MT-II)
- Research class
- Cyclic alpha-MSH analogue; nonselective melanocortin-receptor agonist
- Evidence reviewed
- Receptor assays, medicinal chemistry, animal neuroscience, and small early human studies
- Review date
- September 21, 2026
This article is an educational summary for qualified laboratory and analytical research. It is not medical advice and does not provide instructions for human or veterinary use. JD BioWorks materials are not for injection, ingestion, administration, application, or other use in humans or animals.
Related Research Materials
Melanotan II
Melanotan II 10 mg research material. Lot-specific analytical documentation is available below.
View Research Material